Latest Breaking News On - Juanc varela - Page 1 : vimarsana.com

NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K

- Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 . | June 5, 2023

United statesOhio state universityEmily luSumithira vasuSuzanne afonso smithJuanc varelaRobertd knightKristi jonesMonzrm al malkiMathias oelkeSojung kimCorporate affairsDivision of oncologyAdvent health bloodDivision of hematologyKarmanos cancer center wayne state university

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOhio state universityMonzrm al malkiJuanc varelaSumithira vasuKristi jonesRobertd knightSuzanne afonso smithMathias oelkeSojung kimEmily luCity of hope national medical centerExchange commissionMarrow transplant programDivision of hematologyKarmanos cancer center wayne state university

NexImmune (NEXI) Presents Initial Positive Data from the NEXI-001 Phase 1 Trial

NexImmune (NEXI) Presents Initial Positive Data from the NEXI-001 Phase 1 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOhio state universityMonzrm al malkiSumithira vasuRobertd knightSojung kimSuzanne afonso smithEmily luJuanc varelaKristi jonesMathias oelkeAdvent health bloodNeximmune incMarrow transplant programDepartment of internal medicineCity of hope national medical center

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesJuanc varelaRobertd knightScott carmerDaniel bednarikMaung myo htutLauren suarezMathias oelkeVineetha edavanaEmily luSojung kimAmerican society of hematologyExchange commissionNeximmune incCorporate affairsInitial phase

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results

Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionPhase 1/2 study of NEXI-002 as a monotherapy.

United statesJuanc varelaRobertd knightScott carmerDaniel bednarikMaung myo htutLauren suarezMathias oelkeVineetha edavanaEmily luSojung kimAmerican society of hematologyExchange commissionNeximmune incCorporate affairsInitial phase